CDK7

Edgewood Oncology Announces Positive Efficacy Data From Investigator-Sponsored Study of BTX-A51 in Preclinical Models of Liposarcoma

Retrieved on: 
Sunday, April 7, 2024
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, Bone marrow, CDK7, MDM2, Apoptosis, BH3, CDK, AML, Dana–Farber Cancer Institute, Patient, LPS, Neoplasm, DNA, Cancer, Liposarcoma, Clinical trial, Azacitidine, CDK9, MCL1, Vaccine

The presentation (Abstract 604), “Targeting casein kinase 1 alpha (CK1alpha) and transcriptional CDKs (CDK7/9) in human liposarcomas,” highlighted findings for BTX-A51 in preclinical human models of LPS.

Key Points: 
  • The presentation (Abstract 604), “Targeting casein kinase 1 alpha (CK1alpha) and transcriptional CDKs (CDK7/9) in human liposarcomas,” highlighted findings for BTX-A51 in preclinical human models of LPS.
  • The data demonstrate that BTX-A51 has preclinical efficacy in treating patient-derived LPS in cell lines and human xenograft models and provides insight into the synergy gained by inhibiting both CK1α and CDK9.
  • “Dedifferentiated liposarcomas (DDLPS) are rare tumors derived from precursors of fat cells which can occur anywhere in the body.
  • Importantly, preliminary in vivo data in an LPS patient-derived xenograft model reveal that BTX-A51 is well-tolerated under conditions that inhibit tumor growth.

Edgewood Oncology Emerges From Stealth with $20 Million in Series A Financing to Advance BTX-A51 in Patients with Hematologic Malignancies and Genetically-Defined Solid Tumors

Retrieved on: 
Monday, March 25, 2024
Science, Biotechnology, Research, Oncology, General Health, Health, Genetics, Clinical Trials, Toxicity, CDK7, Apoptosis, Hebrew University of Jerusalem, CRH, CRi, AML, Patient, Immunology, Acute myeloid leukemia, Cancer, Medicine, Alta Partners, Therapy, Drug development, Breast cancer, Safety, Azacitidine, Pharmacokinetics, CDK9, Bone marrow, Pharmaceutical industry

Edgewood acquired the rights to BTX-A51 from Yissum, the technology transfer company of The Hebrew University of Jerusalem, in 2023 and will use the Series A funding to advance efficacy studies in AML and breast cancer.

Key Points: 
  • Edgewood acquired the rights to BTX-A51 from Yissum, the technology transfer company of The Hebrew University of Jerusalem, in 2023 and will use the Series A funding to advance efficacy studies in AML and breast cancer.
  • “We formed Edgewood Oncology because of the synergistic mechanism of action and promising safety and anti-tumor data that was observed with BTX-A51 in Phase 1 in AML and solid tumor patients.
  • In a Phase 1 study in heavily pre-treated R/R AML patients, monotherapy BTX-A51 demonstrated a favorable safety profile and encouraging antileukemic activity.
  • As a next step, Edgewood initiated a study of BTX-A51 in combination with azacitidine in R/R AML patients in December 2023.

Exscientia Business and Financial Update for the Full Year 2023

Retrieved on: 
Thursday, March 21, 2024
Biotechnology, Pharmaceutical, Oncology, Health, Artificial Intelligence, Health Technology, Technology, Clinical Trials, Research, Federal Reserve Bank, Automation, Ovarian cancer, DSM-IV codes, CDK7, Learning, LSD1, Bill, Half-life, UGT1A1, International, Inflammation, Patient, EDT, G&A, Cancer, AI, Bristol Myers Squibb, IND, Medicine, Merck Group, Sumitomo Pharma, PKC, ID, GMT, MALT1, Acute leukemia, Pharmaceutical industry

Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the fourth quarter and full year 2023, are summarised below.

Key Points: 
  • Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the fourth quarter and full year 2023, are summarised below.
  • Exscientia will host a conference call Thursday, March 21 at 12:30 p.m. GMT / 8:30 a.m. EDT.
  • This study has the potential to support the ongoing development of ‘539, Exscientia’s LSD1 inhibitor
    In July 2023, Exscientia launched EXCYTE-1, a first-of-its-kind prospective observational study in ovarian cancer.
  • A replay will be available for 90 days under “Events and Presentations” in the “Investors and Media” section of the Exscientia website .

Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, February 27, 2024
CDK4, ESPP, Research, BCL6, Sale, Exercise, LRRK2, ARVN, CDK7, ATM, HER2, Genentech, European Medicines Agency, Congress, Development, Breast cancer, Pfizer, CBR, ESMO, Everolimus, Greyhawk, ESR1, Oncology, Enrollment, Investment, Insurance, Prostate cancer, PFS, Food, Ribociclib, Bayer, Administration, Patient, Neutropenia, Pharmaceutical industry

NEW HAVEN, Conn., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • Median PFS of 11.1 and 11.0 months in patients with ESR1 wild-type and ESR1 mutant tumors, respectively.
  • Announced the appointment of Randy Teel, Ph.D., Arvinas’ current senior vice president of corporate and business development, to the role of interim chief financial officer and treasurer.
  • The Arvinas Board of Directors has launched a formal search process to identify Mr. Cassidy’s permanent replacement.
  • Revenues: Revenue was $78.5 million and $(43.1) million for the year and quarter ended December 31, 2023 as compared with $131.4 million and $38.0 million for the year and quarter ended December 31, 2022.

Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer

Retrieved on: 
Wednesday, February 14, 2024
Proteolysis, Woman, Chimera, Clinical trial, ID, PFE, CDK7, Breast, Safety, Therapy, Patient, Pharmaceutical industry

“We’re excited to expand clinical development of samuraciclib with our Phase 1b/2 clinical trial evaluating the combination of samuraciclib and vepdegestrant, another step forward in addressing an important need for patients with advanced breast cancer,” said Tim Pearson, Chief Executive Officer of Carrick Therapeutics.

Key Points: 
  • “We’re excited to expand clinical development of samuraciclib with our Phase 1b/2 clinical trial evaluating the combination of samuraciclib and vepdegestrant, another step forward in addressing an important need for patients with advanced breast cancer,” said Tim Pearson, Chief Executive Officer of Carrick Therapeutics.
  • “We believe there is great potential for this combination treatment, based on the encouraging initial clinical trial data for vepdegestrant and Pfizer’s deep expertise in developing treatments for breast cancer.”
    The Phase 1b/2 clinical trial has two parts.
  • In Phase 1b, escalating doses of samuraciclib and vepdegestrant will be tested to determine appropriate doses of each therapy to be used in combination.
  • This clinical trial evaluating the novel combination of samuraciclib and vepdegestrant is being conducted as part of the TACTIVE-U study in collaboration with Arvinas and Pfizer under a clinical trial collaboration and supply agreement.

Carrick Therapeutics Announces First Patient Dosed in Phase 2b Clinical Trial of Samuraciclib in Combination with Fulvestrant in Patients with Advanced HR+, HER2- Breast Cancer

Retrieved on: 
Friday, December 15, 2023
CDK7, Woman, Breast cancer, Fulvestrant, Therapy, Clinical trial, ID, Patient, Female, Pharmaceutical industry

“We continue to make great progress in evaluating the combination of samuraciclib and fulvestrant with the dosing of the first patient in the Phase 2b study,” said Tim Pearson, Chief Executive Officer of Carrick Therapeutics.

Key Points: 
  • “We continue to make great progress in evaluating the combination of samuraciclib and fulvestrant with the dosing of the first patient in the Phase 2b study,” said Tim Pearson, Chief Executive Officer of Carrick Therapeutics.
  • “There is a large unmet need in treatment for women with HR+, HER2- breast cancer, which represents more than two thirds of all new female breast cancer cases.
  • We previously announced data from a single-arm Ph2a study with this combination therapy that demonstrated both clinical activity and tolerability.
  • Clinical trial details can also be found on www.clinicaltrials.gov under study ID: NCT05963984.

Exscientia Business Update for Third Quarter 2023

Retrieved on: 
Thursday, November 9, 2023
Biotechnology, Pharmaceutical, Oncology, Health, Artificial Intelligence, Health Technology, Technology, Clinical Trials, Research, Drug design, GBP, NSCLC, IND, MALT1, ESMO, Ovarian cancer, International, GMT, EST, Congress, Head, European Society for Medical Oncology, G&A, PKC, Colorectal cancer, Acute leukemia, Acquisition, Federal Reserve Bank, BMS, Growth, CDK7, ID, Risk, Bristol Myers Squibb, Jaundice, Merck Group, Pancreatic cancer, AlphaFold, Sumitomo Pharma, Lung cancer, LSD1, USD, AI, Berlin, Patient, Toxicity, AML, Automation, Pharmaceutical industry, Medical imaging, Rare-earth element, Fine chemical, Cryptocurrency, Bank, Sanofi

Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the third quarter of 2023, are summarised below.

Key Points: 
  • Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the third quarter of 2023, are summarised below.
  • Exscientia will host a conference call Thursday, November 9 at 1:30 p.m. GMT / 8:30 a.m. EST.
  • A replay will be available for 90 days under “Events and Presentations” in the “Investors and Media” section of the Exscientia website .
  • The increase in revenue quarter over quarter was primarily due to $8.38 million in revenue recognised from the projects that Exscientia and BMS mutually determined not to proceed with further development of under the BMS collaboration.

Carrick Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Samuraciclib in Combination with Elacestrant in Patients with Advanced Breast Cancer

Retrieved on: 
Wednesday, October 18, 2023
SERD, Clinical trial, Menarini, Pharmacokinetics, CDK7, ID, Biology, Woman, Therapy, Liquid biopsy, Patient, HR, Pharmaceutical industry

"Dosing the first patient in our Phase 2 clinical trial evaluating the combination of samuraciclib and elacestrant is an important milestone in our goal of improving outcomes for women fighting metastatic breast cancer,” said Tim Pearson, Chief Executive Officer of Carrick Therapeutics.

Key Points: 
  • "Dosing the first patient in our Phase 2 clinical trial evaluating the combination of samuraciclib and elacestrant is an important milestone in our goal of improving outcomes for women fighting metastatic breast cancer,” said Tim Pearson, Chief Executive Officer of Carrick Therapeutics.
  • The Phase 2 clinical trial evaluating the novel combination of samuraciclib and elacestrant is being conducted in collaboration with Menarini, pursuant to a clinical trial collaboration and supply agreement for elacestrant.
  • Clinical trial details can also be found on www.clinicaltrials.gov under study ID: NCT05963997 .
  • For additional information on the clinical trial, please contact [email protected] .

Exscientia Details Pipeline Prioritisation Strategy

Retrieved on: 
Tuesday, October 3, 2023
Research, Technology, Clinical Trials, Software, Pharmaceutical, Health, Data Management, Science, Oncology, Artificial Intelligence, Pancreatic cancer, Tissue, Carcinoma, LSD1, Partnership, Acute leukemia, ESMO, Therapeutic index, Pharmacokinetics, CDK7, Merck Group, Lung cancer, CNS, SCLC, AML, Investment, Patient, Standard of care, Colorectal cancer, Medicine, UGT1A1, A2A, Ovarian cancer, Automation, Pharmaceutical industry, Medical imaging

Exscientia plc (Nasdaq: EXAI) today provided an update on its pipeline prioritisation strategy designed to further strengthen the Company’s focus, investment and infrastructure on programmes of greatest potential for differentiation and value creation.

Key Points: 
  • Exscientia plc (Nasdaq: EXAI) today provided an update on its pipeline prioritisation strategy designed to further strengthen the Company’s focus, investment and infrastructure on programmes of greatest potential for differentiation and value creation.
  • Exscientia has built a highly efficient and versatile AI-led drug discovery platform.
  • This strategic focus is designed to allow Exscientia to maximise its pipeline value and output while continuing to develop novel technologies to transform drug discovery and development.
  • “Exscientia creates value by using technology to solve previously unsolved discovery challenges and achieving great data-driven operating efficiency,” said Professor Andrew Hopkins FRS FMedSci, founder and Chief Executive Officer of Exscientia.

Exscientia Business Update for Second Quarter and First Half of 2023

Retrieved on: 
Thursday, August 10, 2023
Research, Pharmaceutical, Oncology, Technology, Artificial Intelligence, Health Technology, Clinical Trials, Science, Biotechnology, Other Technology, Other Science, Health, Pancreatic cancer, Federal Reserve Bank, LSD1, International, Sumitomo Pharma, IGNITE, Pharmacokinetics, CDK7, Head, G&A, PKC, NSCLC, Bristol Myers Squibb, Lung cancer, Harvard University, ID, EDT, USD, MALT1, Publication, Patient, Machine learning, Medicine, Growth, AI, Ovarian cancer, GBP, Safety, Automation, BST, Communications satellite, Pharmaceutical industry, Management, Cryptocurrency, Rare-earth element, Bank, Sanofi

Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the second quarter and first half 2023, are summarised below.

Key Points: 
  • Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the second quarter and first half 2023, are summarised below.
  • “In the first half of 2023, four molecules precision-designed by Exscientia advanced further into clinical trials, a significant achievement as we progress our growing pipeline,” said Professor Andrew Hopkins FRS FMedSci, founder and Chief Executive Officer of Exscientia.
  • Research and development expenses in the second quarter 2023 were relatively flat over the second quarter 2022, as areas of pipeline and operational growth were offset by efficiency and cost savings activities.
  • Cash inflows: For the second quarter 2023, Exscientia received $0.7 million in cash inflows from its collaborations as compared to $111.0 million during the second quarter 2022, when the upfront payment for the Sanofi collaboration was received.